JSA in Germany with BfArM/PEI and G-BA
|
|
|
- Cameron Hill
- 9 years ago
- Views:
Transcription
1
2 JSA in Germany with BfArM/PEI and G-BA 16 th DGRA Annual Congress Bonn, 8 May 2014 Thomas Mueller Head of Pharmaceuticals Department Federal Joint Committee (GBA)
3 Seite Thomas Müller AMNOG in brief
4 Assessment Principles - Key Point What is the additional benefit over the appropriate comparator (standard treatment)? Quantitative extent of additional benefit? Differences between subpopulations of patients? Patient-relevant endpoints: mortality, morbidity, quality of life, adverse events? Surrogate endpoints: Validation for patient-relevant endpoints? Biomarkers for relevant populations of patients? Lack or gaps of evidence, additional study requirements? Re-assessment after period of time? Seite Thomas Müller
5 Results (February 2014, since 2011) Seite Thomas Müller
6 Resolution by therapeutic area - examples Resolutions in Diabetes (February 2014) Resolutions in Oncology (February 2014) Seite Thomas Müller
7 Price Negotiations - results arbitration decisions market exit between manufacturer and organization of statutory health insurance funds (on the basis of the G-BA resolutions) completed Price negotiations 41 Arbitrations decisions 3 Market exit: (Aliskiren/amlodipine, collagenase clostridium histolyticum, linagliptin, linaclotide, lixisenatide, retigabine) 6 Seite Thomas Müller
8 Outcome AMNOG Free pricing for newly introduced drugs is replaced by negotiation on the basis of an early benefit assessment No CBA, no CEA (no ICER, no threshold) Unchanged: Early market entry and drug availability in Germany, even for expensive drugs Free pricing for first 12 months Market launch and early benefit assessment in parallel AMNOG does not hinder innovation; it promotes intense discussion on open scientific questions and values Seite Thomas Müller
9 Five Ws of Consultations WHO? G-BA advices industry WHAT? In particular advice on: - Appropriate comparator, - Study design, - Endpoints, Biomarkers, Surrogates, - Patient groups. WHEN? Best before phase III, but any time is possible (e.g. phase IV) WHERE? At the G-BA office, Berlin (teleconference is possible) WHY? Assistance to undergo the procedure Seite Thomas Müller
10 Consultations with the G-BA: course Request for consultation Discussion within G-BA (working group, subcommittee): Proposal by secretary, agreement on key points At week 8: Consultation meeting with meeting minutes Meeting minutes have to be attached to the future dossier If necessary: new consultation on comments of the pharmaceutical company at the G-BA office Fees apply depending on complexity and scope of questions Free of charge: Written answers concerning questions concerning procedures or dossier submission Seite Thomas Müller
11 Consultations with the G-BA: course Request for consultation Comments If necessary Check completeness, Processing request Literature review, evidence synopsis G-BA Working group, subcommittee Consultation meeting Meetin g minutes If applicable Week 8 Comments to questions regarding regulatory affairs Seite Thomas Müller
12 Participation of BfArM or PEI (national regulatory authorities) - Standard involvement (legal base SGB V 35b Abs. 7) - Before phase III trial or during planning of a new clinical study Course: Request for consultation before phase III or during planning of clinical study BfArM or PEI will be informed and get questions & complete dossier (exception: pharmaceutical company excludes participation) Comments of BfArM or PEI (on market authorisation aspects) Discussion within G-BA (considering BfArM / PEI comments) Consultation meeting with meeting minutes Comments of pharmaceutical company on meeting minutes If applicable new consultation on comments of the pharmaceutical company and change of meeting minutes BfArm or PEI get copy of final meeting minutes (exception: if pharmaceutical company denies) Seite Thomas Müller
13 Consultation: Documents Documents to submit: - Request form /#abschnitt-2 - Filled in German (therapeutic area, question, positions) - Attachments in English accepted (e.g. Study protocols, literature) - Minutes of advice meetings with regulatory authorities - Concept of clinical studies if applicable #abschnitt-7 Documents provided after the advice meeting - Meeting minutes - Systematic literature survey (standard treatments in the claimed indication) - Overview about all treatments considered as comparator - Comments of BfArM or PEI on marketing authorization aspects (if applicable) Seite Thomas Müller
14 Consultations: Facts and Figures Number of consultations Seite Thomas Müller
15 Consultations: Facts and Figures proportion of topics - Main focus on questions regarding comparator - Increasing interest on comments to study design - Questions regarding procedure drop Seite Thomas Müller
16 Consultations: Facts and Figures selected therapeutics areas Seite Thomas Müller
17 Experiences from interaction with regulatory bodies Dealing with comparators: lack of evidence, off-label-use, no comparators, missing data accessibility Dealing with (patient relevant) endpoints and validity Dealing with surrogates (incl. discussions with experts) Dealing with conditional approval (time limited resolutions) Data generation after authorization (safety and efficacy) Dealing with uncertainties: early crossover, open label studies, indirect comparison, Study population: label differs from investigated population Seite Thomas Müller
18 Pilot- /Project- joint/parallel advice with EMA and other European HTA agencies (May 2014) Pilots EUnetHTA (Lead Partner HAS, France): 10 G-BA participations Pilots of multi-stakeholder consultations in early-stage drug development, EMA: 10 G-BA participations Seite Thomas Müller
19 Interaction G-BA Regulators - HTA HTA Network activities (BMG/G-BA) EMA-multi-HTA Pilots for parallel scientific advice EUnetHTA JA Scientific and technical cooperation SEED (Shaping European Early Dialogues) multi-hta pilots Seite Thomas Müller
20 Parallel Scientific advice (EMA + HTAs) EMA/HTA Company GBA [G-BA consultation procedure] Letter of Intent Briefing book Prevalidation TC with copany Distribution to participating agencies Request for advice EMA: list of open issues TC Response Meeting with individual respons e of agencies Mee ting min utes com ment s (HTA only) - 4 mo day 0 day 15 day 30 day 45 day 90 Seite Thomas Müller
21 Early Dialogue SEED / Eunetha EUnetHTA Company Letter of Intent (early dialog ues@ hassante. fr) List of clarifications Briefing book Prevalidation Distribution to HTA TC Resp onse Distribution to HTA TC Meeting with individual respons e of HTA Mee ting min utes com ment s - 4 mo day 0 day 15 day 30 day 45 day 90 day 100 Seite Thomas Müller
22 Licensing and HTA: Harmonization? Licensing: Focus on safety and product quality HTA: Focus on (additional) benefit, value, listing decisions, reimbursement, budgets, allocation, opportunity costs Clinical trials = evidence basis for both licensing and HTA decisions Clinical trials = need early & global organization, resources (human, financial and time) Possible harmonization for: study design, patient groups, integration of standard of care (active control), relevant endpoints, relevant clinical difference (effect size) No harmonization for: appraisal of effects, listing decisions, willingness (and ability) to pay EMA/HTA advices: first positive step, but need for further development (legal framework, coordination, HTA involvement) Seite Thomas Müller
23 Transparency of information Seite Thomas Müller
24 Seite Thomas Müller
Endpoints and quality of life
Endpoints and quality of life PFS, OS, quality of life and medico-economic assessment in oncology Isabelle Durand-Zaleski, Jérôme Garnier, Mira Pavlovic, and participants of roundtable n 3 Pascal Bilbault,
Moderator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
HTA and Post-Launch Studies
EXPLORING THE FUTURE OF RE FOR DRUGS IN EUROPE ELEMENTS AFFECTING THE FUTURE OF RE IN EUROPE? Baseline factors Payers continue to face austerity pressures Decision making by Payer / HTA bodies remains
HTA NETWORK MULTIANNUAL WORK PROGRAMME 2016-2020
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Healthcare systems, medical products and innovation Medical products: quality, safety, innovation Brussels, 20 May 2016 HTA NETWORK MULTIANNUAL
The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
Guideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
Regulatory Writing Clinical Project Management Strategic Communications
Regulatory Writing Clinical Project Management Strategic Communications FLEXIBLE. STRATEGIC. INFORMED. COMPLIANT. For over 15 years, Niche Science and Technology has been providing outstanding medical
HTA Uncovered. The introduction of economic evaluations have hitherto not influenced ASMR ratings claimed by manufacturers in France
Issue No. 8 June 0 HTA Uncovered The introduction of economic evaluations have hitherto not influenced ASMR ratings claimed by manufacturers in France Since the publication of the 008 Social Security Financing
Key considerations for outsourcing late phase clinical research
Key considerations for outsourcing late phase clinical research Alan Nelson (on behalf of Van Zyl Engelbrecht) Senior Project Director at UBC: An Express Script Company Layout of presentation My presentation
The Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA
Medpace Discovery Series presents Proof-of-Concept Studies and the End of Phase IIa Meeting with the FDA DR. JIM WEI: Today my topic is going to be Proof-of-Concept Studies and FDA End of Phase 2a Meetings
EU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
Best Practice guidance for Pilot EMA HTA Parallel Scientific Advice procedures
1 2 3 7 May 2014 EMA/109608/2014 Human Medicines Development and Evaluation 4 5 6 Best Practice guidance for Pilot EMA HTA Parallel Scientific Advice procedures For consultation 7 8 9 10 11 12 13 14 15
Managing challenges in early drug development: Biologicals and small molecules
AGAH and Club Phase-I: 3rd Joint Annual Meeting Managing challenges in early drug development: Biologicals and small molecules Tuesday, April 28, 2009 and Wednesday, April 29, 2009 ESPACE TETE D`OR, LYON,
The EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
9th DGRA Annual Congress
Bundesinstitut für Arzneimittel und Medizinprodukte 9th DGRA Annual Congress Electronic Regulatory Submission from the Point of View of the National Drug Agencies - Germany Dr. Klaus Menges, BfArM 13.06.2007,
Overview of FDA Expedited Programs with a Focus on Breakthrough Therapy
Overview of FDA Expedited Programs with a Focus on Breakthrough Therapy Miranda Raggio, RN, BSN, MA CDER Breakthrough Therapy Program Manager Regulatory Affairs Team Office of New Drugs, CDER Overview
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary
An analysis of the EUnetHTA pilot assessments
Prepared For: EFPIA Leopold Plaza Building, Rue du Trône 108 B-1050 Brussels (Belgium) An analysis of the EUnetHTA pilot assessments Prepared By: Tim Wilsdon, Michele Pistollato, Lilian Li and Artes Haderi
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
Cost-Benefit and Cost-Effectiveness Analysis. Kevin Frick, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
Decentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000
An Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
Response of the German Medical Association
Response of the German Medical Association to the European Commission proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and
Approval rating: how do the EMA and FDA compare?
Approval rating: how do the EMA and FDA compare? MARC BEISHON When new cancer therapies regularly become available more than half a year earlier in the US than in Europe, or get regulatory approval on
Patients with confirmed relapse 111 26 (23.4 %) 104 16 (15.4 %) 1.52 [0.87; 2.67] p = 0.143 Probability of a relapse by week 96
![Patients with confirmed relapse 111 26 (23.4 %) 104 16 (15.4 %) 1.52 [0.87; 2.67] p = 0.143 Probability of a relapse by week 96](/thumbs/33/15779352.jpg "Patients with confirmed relapse 111 26 (23.4 %) 104 16 (15.4 %) 1.52 [0.87; 2.67] p = 0.143 Probability of a relapse by week 96")
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
Template for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
Strategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA
Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why
The Value of A Qualified Outcome Measure Janet Woodcock, M.D.
The Value of A Qualified Outcome Measure Janet Woodcock, M.D. The Critical Path Institute (CPI) Multiple Sclerosis Outcome Assessments Consortium (MSAOC) 1 April 2013 White Oak 1 Overview of Workshop Create
Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
The Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
Improving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses: An International Perspective
Improving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses: An International Perspective by Gerry Fairbrother, Ph.D.; Ellen O Brien, Ph.D.; Rosina Pradhananga, M.P.H.; Kalipso
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
Evaluation of Treatment Pathways in Oncology: Modeling Approaches. Feng Pan, PhD United BioSource Corporation Bethesda, MD
Evaluation of Treatment Pathways in Oncology: Modeling Approaches Feng Pan, PhD United BioSource Corporation Bethesda, MD 1 Objectives Rationale for modeling treatment pathways Treatment pathway simulation
How To Understand The Paediatric Regulation
Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Objectives. P&T Committee. P&T Committee Structure. Utilization of P&T Committees
Objectives Discuss overview of forum purpose. Drug Information used in the Managed Care Pharmacy P&T Decision Making Process: Current Practice and Insights Diana Brixner, RPh, PhD Professor and Chair,
The fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation
Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation Joint BBS-EFSPI Seminar, Basel, 13 Nov 2014 Sabine Atzor, Head of EU Regulatory Policies PDR Overview
Marketing Authorization Procedures in the European Union Making the Right Choice
Life science i technical bulletin ISSUE N 33 /DECEMBER 2009 Marketing Authorization Procedures in the European Union Making the Right Choice AUTHOR: Arash Ghalamkarpour, PhD, Regulatory Affairs Associate,
Regulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
E. Specific requirements for innovation procurement (PCP/PPI) supported by Horizon 2020 grants
E. Specific requirements for innovation procurement (PCP/PPI) supported by Horizon 2020 grants The following requirements apply to PCPs and PPIs for which the tender preparation and/or the call for tender
The European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report Questions & Answers
E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report & Current version dated 31 March International Conference on Harmonisation of Technical Requirements
The Main Challenges around IDMP 1 and Ways to Solve Them. Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany
The Main Challenges around IDMP 1 and Ways to Solve Them Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany Abstract: As of 1 July 2016, pharmaceutical companies which develop and
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
HMPWG in the view of the NCA
EMEA Homeopathic Workshop Bundesinstitut für Arzneimittel London, 27.10.2006 HMPWG in the view of the NCA Objectives, Achievements, Roles and Responsibilities Werner Knöss Head of Division Complementary
The Quality System for Drugs in Germany
The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute
DZIF-Product Development Unit (PDU)
November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &
through advances in risk-based
Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform
White Paper The EU Clinical Trials Regulation Main Changes and Challenges
White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society
Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics
Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
EMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
![Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)](/thumbs/26/8616095.jpg "Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)")
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
Course Certificate In. Pharmaceuticals and Medical Research: Clinical Research Monitoring & Coordination
Course Certificate In Pharmaceuticals and Medical Research: Clinical Research Monitoring & Coordination Welcome to the latest in distance learning courses designed to prepare you, on your own schedule,
Overview. Health Science Authority. Implementation of ICH guideline in Singapore. Singapore s experience
ICH and Singapore Dr Christina Lim Deputy Group Director, Health Product Regulation Group Senior Advisor, International Collaboration Health Sciences Authority Singapore November 2008 Overview Health Science
EUROPEAN INDUSTRIAL PHARMACISTS GROUP
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guide to Good Regulatory Practice Acknowledgments: Valérie LACAMOIRE, Conseil Central de la section B de l Ordre des Pharmaciens Kelsey MOWER, Industrial Pharmacists
A clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
History and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
pcodr Performance Metrics Report
pcodr Performance Metrics Report April 2015 TABLE OF CONTENTS EXECUTIVE SUMMARY...ii Operations...ii Transparency...ii Stakeholder Engagement... iii Looking Ahead... iii 1. INTRODUCTION... 1 2. PERFORMANCE
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche,
Comité Economique des Produits de Santé
Comité Economique des Produits de Santé Summary of the activity report for 1999 CEPS 8 avenue de Ségur 75350 Paris SP 07 Activity Report for 1999 1 In accordance with Article D.162-2-5 of the Social Security
Glossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
An introduction to value-based healthcare in Europe
An article from The Economist Intelligence Unit An introduction to value-based healthcare in Europe European governments, like those in other parts of the world, are feeling the strain on their health
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
A comparative analysis of the role and impact of Health Technology Assessment: 2013
Prepared For: PhRMA, Suite 300, 950 F Street, NW, Washington, DC 20004 EFPIA, Leopold Plaza Building, Rue du Trône 108, B-1050 Brussels (Belgium) A comparative analysis of the role and impact of Health
Careers in Medical and Scientific Writing
Careers in Medical and Scientific Writing Laura McCormick, PhD Vice President Associate Practice Leader Tamara Fink, PhD Associate Scientific Director ProEd Communications, Inc Beachwood, Ohio Agenda Introduction
HEALTH ECONOMICS AND OUTCOMES RESEARCH SERVICES
HEALTH ECONOMICS AND OUTCOMES RESEARCH SERVICES Health Economics and Outcomes Research cannot operate in a silo. An optimal value proposition requires strong and robust HEOR statements. We develop the
Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans
Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans C. Daniel Mullins, PhD Professor Pharmaceutical Health Services Research Department University
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
Submission of a clinical trial for access to ECRIN services Notice to the Applicant
Submission of a clinical trial for access to ECRIN services Notice to the Applicant BEFORE SUBMITTING YOUR PROTOCOL Please, contact the European Correspondent (EuCo) in your country. The list of EuCos
The New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
EU Pricing & Reimbursement
EU Pricing & Reimbursement Pricing & reimbursement schemes in major European countries Contents Introduction 1 Belgium 2 The Czech Republic 8 Germany 13 France 23 NOVEMBER Italy 30 The Netherlands 35 Spain